View Filing Data

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2017	Mar. 16, 2018	Jun. 30, 2017
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Entity Registrant Name	TAPIMMUNE INC.
Entity Central Index Key	0001094038
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 30,500,000
Trading Symbol	TPIV
Entity Common Stock, Shares Outstanding		10,626,140

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash	$ 5,129,289	$ 7,851,243
Prepaid expenses and deposits	51,150	70,149
Total current assets	5,180,439	7,921,392
Total assets	5,180,439	7,921,392
Current liabilities:
Accounts payable and accrued liabilities	1,508,312	1,224,940
Research agreement obligations	0	492,365
Warrant liability	9,000	14,500
Promissory note	5,000	5,000
Total current liabilities	1,522,312	1,736,805
Total liabilities	1,522,312	1,736,805
COMMITMENTS AND CONTINGENCIES
Stockholders' equity:
Common stock, $0.001 par value, 41.7 million shares authorized, 10.6 million and 8.4 million shares issued and outstanding as of December 31, 2017 and 2016, respectively	10,616	8,421
Additional paid-in capital	161,067,538	151,991,974
Accumulated deficit	(157,420,027)	(145,815,808)
Total stockholders' equity	3,658,127	6,184,587
Total liabilities and stockholders' equity	5,180,439	7,921,392
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, Value	0	0
Series B Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, Value	$ 0	$ 0

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	5,000,000	5,000,000
Common stock shares par value	$ 0.001	$ 0.001
Common stock shares authorized	41,700,000	41,700,000
Common stock shares issued	10,600,000	8,400,000
Common stock shares outstanding	10,600,000	8,400,000
Series A Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,250,000	1,250,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Series B Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,500,000	1,500,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Operating expenses:
Research and development	$ 5,250,985	$ 3,800,035
General and administrative	6,412,121	4,692,234
Total operating expenses	11,663,106	8,492,269
Loss from operations	(11,663,106)	(8,492,269)
Other income (expense):
Change in fair value of warrant liabilities	5,500	5,939,500
Debt extinguishment gain	492,365	0
Grant income	183,064	231,200
Loss on debt settlement agreements	0	(135,640)
Other income	0	1,828
Net loss	$ (10,982,177)	$ (2,455,381)
Basic net loss per share	$ (1.16)	$ (0.36)
Diluted net loss per share	$ (1.16)	$ (0.72)
Weighted average number of common shares outstanding, basic	9,453,483	6,889,898
Weighted average number of common shares outstanding, diluted	9,453,483	7,420,995

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Total	Common Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]
Beginning Balance, Amount at Dec. 31, 2015	$ (21,360,356)	$ 5,884	$ 112,142,187	$ (133,508,427)
Beginning Balance, Share at Dec. 31, 2015		5,882,976
Private placement (net of offering cost), Amount	2,331,126	$ 653	2,330,473	0
Private placement (net of offering cost), Share		653,166
Fair value of shares issued as inducement on August 10, 2016, Amount	0	$ 750	4,499,250	(4,500,000)
Fair value of shares issued as inducement on August 10, 2016, Share		750,000
Fair value of series F and F-1 warrants issued as inducement in August 2016	0	$ 0	5,352,000	(5,352,000)
Exercise of warrants, Amount	5,483,349	$ 1,000	5,482,349	0
Exercise of warrants, Share		1,000,000
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements	15,465,000	$ 0	15,465,000	0
Fair value of repriced warrants as inducement	5,074,000	0	5,074,000	0
Exercise of stock options	18,125	$ 10	18,115	0
Exercise of stock options, Share		10,417
Shares issued in debt settlement agreements, Amount	70,315	$ 10	70,305	0
Shares issued in debt settlement agreements, Share		10,191
Stock- based compensation, Amount	1,558,409	$ 114	1,558,295	0
Stock- based compensation, Share		114,435
Net loss	(2,455,381)	$ 0	0	(2,455,381)
Ending Balance, Amount at Dec. 31, 2016	6,184,587	$ 8,421	151,991,974	(145,815,808)
Ending Balance, Share at Dec. 31, 2016		8,421,185
Common stock and warrants issued in private placement, Amount	6,190,003	$ 1,504	6,188,499	0
Common stock and warrants issued in private placement, Share		1,503,567
Fees and legal costs relating to private placement	(781,660)	$ 0	(781,660)	0
Exercise of warrants, Amount	666,666	$ 168	666,498	0
Exercise of warrants, Share		167,926
Legal costs relating to exercise of warrants	(47,043)	$ 0	(47,043)	0
Fair value of repriced warrants as inducement	0	0	622,042	(622,042)
Stock- based compensation, Amount	2,738,244	$ 621	2,737,623	0
Stock- based compensation, Share		620,685
Repurchase of common stock to pay for employee withholding taxes	(310,493)	$ (98)	(310,395)	0
Repurchase of common stock to pay for employee withholding taxes, Shares		(97,639)
Net loss	(10,982,177)	$ 0	0	(10,982,177)
Ending Balance, Amount at Dec. 31, 2017	$ 3,658,127	$ 10,616	$ 161,067,538	$ (157,420,027)
Ending Balance, Share at Dec. 31, 2017		10,615,724

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Cash Flows from Operating Activities:
Net loss	$ (10,982,177)	$ (2,455,381)
Reconciliation of net loss to net cash used in operating activities:
Changes in fair value of warrant liabilities	(5,500)	(5,939,500)
Shares issued in debt settlement agreements	0	70,315
Stock-based compensation	2,738,244	1,558,409
Debt extinguishment gain	(492,365)	0
Changes in operating assets and liabilities:
Prepaid expenses and deposits	18,999	(1,346)
Accounts payable and accrued expenses	283,372	257,582
Net cash used in operating activities	(8,439,427)	(6,509,921)
Cash Flows from Financing Activities:
Proceeds from issuance of common stock and warrants in private placement, net of offering costs	5,408,343	2,331,126
Proceeds from exercise of stock warrants, net of offering costs	619,623	5,483,349
Proceeds from exercise of stock options	0	18,125
Repayment of promissory note	0	(25,000)
Repayment of promissory note - related party	0	(23,000)
Repurchase of common stock to pay for employee withholding taxes	(310,493)	0
Net cash provided by financing activities	5,717,473	7,784,600
Net (decrease) increase in cash	(2,721,954)	1,274,679
Cash at beginning of period	7,851,243	6,576,564
Cash at end of period	5,129,289	7,851,243
Supplemental schedule of non-cash financing activities:
Fair value of repriced warrants as inducement	622,042	0
Reclassification of accrued liability upon issuance of common shares relating to Dr. Glynn Wilson’s compensation	0	191,000
Fair value of issuance of series F and F-1 warrants as inducement in August 2016	0	5,352,000
Fair value of shares issued as inducement on August 10, 2016	0	4,500,000
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements	0	15,465,000
Reclassification of Derivative Warrant Liabilities to Equity at exercise date	$ 0	$ 5,074,000

NATURE OF OPERATIONS

12 Months Ended

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

Note 1:

Nature of Operations

TapImmune Inc. (the “Company”), a Nevada corporation incorporated in 1991, is a biotechnology company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells (CD8+) and T-helper (CD4+) cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.

A Phase I study at the Mayo Clinic, Rochester, MN, evaluating the safety and immune responses of a set of proprietary HER2/neu+ antigens has been successfully completed and the results led to the decision to proceed with Phase II clinical studies in 2017.

A separate Phase I study has also been conducted at Mayo Foundation (“Mayo”) in ovarian and breast cancer (Folate Receptor Alpha). Folate Receptor Alpha is expressed in nearly 50% of breast cancers and in addition, over 95% of ovarian cancers, for which the only treatment options are surgery and chemotherapy, leaving a very important and urgent clinical need for a new therapeutic. Time to recurrence is relatively short for this type of cancer and survival prognosis is extremely poor after recurrence. In the USA alone, there are approximately 30,000 ovarian cancer patients newly diagnosed every year. These Folate Receptor Antigens are applicable to ovarian and triple-negative breast cancer. Both of these diseases have few treatment options if any beyond surgery and chemotherapy and therefore the Company is hopeful that it might be an ideal candidate for orphan drug status in these indications. This study has been successfully completed and the results led to the decision to proceed with multiple Phase II studies in 2017.

In addition, enhancing the visibility of cancer or infected cells to a patient’s immune system is a critical aspect of an effective vaccine. In this regard, TapImmune’s PolyStart™ nucleic acid-based technology provides a four-fold increase in target cell specific naturally processed antigenic epitopes on a cells surface. This increased cell surface presentation corresponding increases activated Helper and/or long-lived Killer T-cell populations that then effectively seek out and work to destroy a patient’s cancer cells.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Note 2:

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

These financial statements are presented in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Principles of Consolidation

These financial statements include the accounts of the Company and its wholly-owned and dormant subsidiary GeneMax Pharmaceuticals Inc. All significant intercompany balances and transactions are eliminated upon consolidation.

Use of Estimates

Preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management’s estimates and assumptions include valuation allowance on deferred tax assets, determining the fair value of stock-based compensation and stock-based transactions, the fair value of the components of the warrant liabilities and accrued liabilities.

Liquidity, financial condition and managements plans

These consolidated financial statements have been prepared on the basis of a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As at December 31, 2017, the Company had cash balances of approximately $5.1 million. Historically, the Company has incurred significant losses in the development of its business. The ability of the Company to continue as a going concern is dependent on raising additional capital to fund current clinical trials, ongoing research and development, maintenance and protection of patents and ultimately on generating future profitable operations. Planned expenditures relating to current and future clinical trials of the Company’s immunotherapy vaccine will require significant additional funding. The Company is dependent on future financings to fund ongoing research and development as well as working capital requirements. The Company’s future capital requirements will depend on many factors including the rate and extent of scientific progress in its research and development programs, the timing, cost and scope involved in clinical trials, obtaining regulatory approvals, pursuing further patent protections and the timing and costs of commercialization activities.

Management is addressing going concern through seeking new sources of capital and is continuing initiatives to raise capital through private placements, related party loans and other institutional sources to meet future working capital requirements. We have no sources of revenue to provide incoming cash flows to sustain our future operations. Our ability to pursue our planned business activities is dependent upon our successful efforts to raise additional capital. These factors raise substantial doubt regarding our ability to continue as a going concern.

Historically, the Company has raised capital through issuances of various financial instruments and during 2016, the Company completed significant restructuring of outstanding debt and equity instruments into equity. Additional capital is required to expand programs including pre-clinical work and to progress clinical trials for the lead vaccine candidates. Strategic partnerships will be needed to continue the product development portfolio and fund development costs. These measures, if successful, may contribute to reduce the risk of going concern uncertainties for the Company beyond the next twelve months.

There is no certainty that the Company will be able to arrange sufficient funding to continue development of products to marketability.

Fair Value Measurements

The Company follows Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures,” (“ASC 820”) for the Company’s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:

•

Level 1 - Quoted prices (unadjusted) in active markets for identical assets and liabilities.

•

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial Instruments and Concentration of Credit Risk.

Patents and Patent Application Costs

Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.

Stock-Based Compensation

The Company incurs stock-based compensation expense related to restricted stock units and stock options. The fair value of restricted stock is determined by the closing market price of the Company's common stock on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards expected to vest on a straight-line basis over the requisite service period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The forfeiture rate is based on historical data, and the Company records stock-based compensation expense only for those awards that are expected to vest. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future:

Expected Term — The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

Expected Volatility — The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

Risk-Free Interest Rate — The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

Expected Dividend — The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received.

Research and Development Costs

The Company has acquired research and development rights to certain technologies. The rights and licenses acquired are considered rights to unproven technology which may not have alternate future uses and therefore, are expensed as incurred as research and development costs.

Clinical trial expenses include direct costs associated with contract research organizations (“CROs”), as well as patient-related costs at sites at which our trials are being conducted. Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved.

The Company incurred costs of approximately $5.3 million and $3.8 million on research and development for the year ended December 31, 2017 and 2016, respectively.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the date of allowances against deferred tax assets.

Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for “unrecognized tax benefits” is recorded for any tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards. As of December 31, 2017 and 2016, no liability for unrecognized tax benefits was required to be reported. The guidance also discusses the classification of related interest and penalties on income taxes. The Company’s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the years ended December 31, 2017 and 2016.

Derivative Liability

The Company evaluates its convertible debt, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. This accounting treatment requires that the carrying amount of embedded derivatives be marked-to-market at each balance sheet date and carried at fair value. In the event that the fair value is recorded as a liability, the change in fair value during the period is recorded in the Statement of Operations as either income or expense. Upon conversion, exercise or modification to the terms of a derivative instrument, the instrument is marked to fair value at the conversion date and then the related fair value is reclassified to equity.

In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.

The classification of financial instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.

Management must determine whether an instrument (or an embedded feature) is indexed to the Company’s own stock. An entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. This exercise affects the accounting for (i) certain freestanding warrants that contain exercise price adjustment features and (ii) convertible notes containing full-ratchet and anti-dilution protections (iii) certain free-standing warrants that contain contingently puttable cash settlement.

Grant Income

The Company recognizes grant income in accordance with the terms stipulated under the grant awarded to the Company’s collaborators at the Mayo Foundation from the U. S. Department of Defense. In various situations, the Company receives certain payments from the U.S. Department of Defense for reimbursement of clinical supplies. These payments are non-refundable, and are not dependent on the Company’s ongoing future performance. The Company has adopted a policy of recognizing these payments as grant income when received.

Loss per Common Share

Basic loss per share include only the weighted average common shares outstanding, without consideration of potentially dilutive securities. Diluted loss per share include the weighted average common shares outstanding and any potentially dilutive common stock equivalent shares in the calculation.

Cash and Credit Risk

The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (“FDIC”) insured limits of $250,000. As of December 31, 2017 and 2016, approximately $4.9 million and $7.6 million, respectively, in cash was uninsured based upon the FDIC insurance coverage limits.

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.

Recent Accounting Pronouncements Adopted in the Year

Going Concern

In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements-Going Concern”, which defines management's responsibility to assess an entity's ability to continue as a going concern, and requires related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. ASU No. 2014-15 is effective for the Company for the fiscal year ending on December 31, 2016, with early adoption permitted. The Company adopted ASU 2014-15 as of December 31, 2017 in its consolidated financial statements and related disclosures, which did not have a material impact on its results of operations, cash flows or financial position.

Deferred Taxes

In November 2015, FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes”. ASU No. 2015-17 requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. ASU No. 2015-17 is effective for financial statements issued for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company adopted ASU No. 2015-17 on January 1, 2017 and its adoption did not have a material impact on the Company’s financial position and results of operations.

Compensation-Stock Compensation

In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting. Under ASU No. 2016-09, companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital (“APIC”). Instead, they will record all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement and the APIC pools will be eliminated. In addition, ASU No. 2016-09 eliminates the requirement that excess tax benefits be realized before companies can recognize them. ASU No. 2016-09 also requires companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. Furthermore, ASU No. 2016-09 will increase the amount an employer can withhold to cover income taxes on awards and still qualify for the exception to liability classification for shares used to satisfy the employer’s statutory income tax withholding obligation. An employer with a statutory income tax withholding obligation will now be allowed to withhold shares with a fair value up to the amount of taxes owed using the maximum statutory tax rate in the employee’s applicable jurisdiction(s). ASU No. 2016-09 requires a company to classify the cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation as a financing activity on the statement of cash flows. Under current U.S. GAAP, it was not specified how these cash flows should be classified. In addition, companies will now have to elect whether to account for forfeitures on share-based payments by (1) recognizing forfeitures of awards as they occur or (2) estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently required. The amendments of this ASU are effective for reporting periods beginning after January 1, 2017, with early adoption permitted but all of the guidance must be adopted in the same period. The Company adopted this on January 1, 2017. The Company has evaluated the impact of ASU No. 2016-09 and has determined that the adoption of the impact of forfeitures, net of income taxes, will not have a material impact on the Company’s future financial statements.

Statement of Cash Flows

In August 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-15, Statement of Cash Flows (Topic 230). This amendment provides guidance on the presentation and classification of specific cash flow items to improve consistency within the statement of cash flows. ASU 2016-15 is effective for fiscal years, and interim periods within those fiscal years beginning after December 15, 2017, with early adoption permitted. The Company adopted this as of December 31, 2017. The Company has evaluated the impact of ASU No. 2016-15 and has determined that the adoption did not have a material impact on the Company’s financial position and results of operations.

Recent Accounting Pronouncements Not Yet Adopted

Accounting for Certain Financial Instruments with Down Round Features

On July 13, 2017, the FASB has issued a two-part Accounting Standards Update (“ASU”), No. 2017-11, (i). Accounting for Certain Financial Instruments with Down Round Features and (ii) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception.

The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 and the interim periods within that annual period. Early adoption is permitted. The Company will be evaluating the impact of adopting this standard on the consolidated financial statements and disclosures.

Compensation-Stock Compensation

In May 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period beginning after December 15, 2017 and interim periods within that annual period. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the consolidated financial statements and disclosures, but does not expect it to have a significant impact.

Revenue from Contracts with Customers

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (ASU 2014-09) as modified by ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,” and ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.” The revenue recognition principle in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies may adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. The Company will adopt the new standard effective January 1, 2018, using the modified retrospective approach. The only impact of the adoption of ASU 2014-09 will be to reclassify the Company's grant income as revenue.

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER

12 Months Ended

Dec. 31, 2017

Noncontrolling Interest [Abstract]

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER

Note 3:

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER

Net Loss per Share Applicable to Common Stockholders

Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similar to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

The following table sets forth the computation of loss per share for the years ended December 31, 2017 and 2016, respectively:

	For the Years Ended
	December 31,
	2017		2016
Numerator:
Net loss	$	(10,982,177)	$	(2,455,381)
Less: non-cash income from change in fair value of common stock warrants		-		(2,856,000)
Net loss - diluted		(10,982,177)		(5,311,381)

Denominator:
Weighted average common shares outstanding - basic		9,453,483		6,889,898
Dilutive effect of warrants, net		-		531,097
Weighted average common shares outstanding - diluted		9,453,483		7,420,995

Net loss per share data:
Basic	$	(1.16)	$	(0.36)
Diluted	$	(1.16)	$	(0.72)

The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

	Year Ended
	December 31,
	2017		2016
Common stock options		489,000		432,000
Common Stock Purchase Warrants		6,521,000		5,060,000
Potentially dilutive securities		7,010,000		5,492,000

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

12 Months Ended

Dec. 31, 2017

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Note 4:

accounts payable and accrued liabilities

Accounts payable and accrued liabilities consist of the following as of December 31, 2017 and 2016, respectively:

	December 31,		December 31,
	2017		2016
Accounts payable	$	1,015,000	$	680,000
Compensation and benefits		162,000		218,000
Professional fees		32,000		53,000
Consulting agreements		-		95,000
Technology license fees		105,000		105,000
Investor relations fees		110,000		-
Other		84,000		74,000
Total accounts payable and accrued liabilities	$	1,508,000	$	1,225,000

RESEARCH AGREEMENT OBLIGATIONS

12 Months Ended

Dec. 31, 2017

Research and Development [Abstract]

RESEARCH AGREEMENTS

Note 5:

Research Agreement OBLIGATIONS

In 2003, the Company entered into a license agreement with a foreign based third-party for certain adenovirus technology. The license agreement was amended several times between inception and 2008 at which time it was amended and restated and had a fixed three-year term expiring in 2011. During such time, the Company did not pursue the technology and has not undertaken further work in the area covered by the technology license. Neither the Company nor the third-party took further actions under or pursuant to the license agreement. The Company carried a historical accrual of approximately $0.5 million under the amended license agreement related to certain obligations provided for in the license agreement. The license agreement was governed by the laws of a foreign jurisdiction. The Company sought and obtained legal advice related to such accrued obligations under the expired license agreement. The Company relied upon a judicial conclusion, as opined upon by outside legal counsel in the applicable foreign jurisdiction, that a court in such foreign jurisdiction would grant relief releasing the Company from liability under the license agreement, and in accordance with Accounting Standards Codification 405 “Extinguishment of Liabilities”, the Company recorded a debt extinguishment gain of $0.5 million and reduced the liability amount owed to $0 during the year ended December 31, 2017.

WARRANT LIABILITY

12 Months Ended

Dec. 31, 2017

Warrant Liability [Abstract]

WARRANT LIABILITY

Note 6:

WARRANT LIABILITY

A weighted average summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the years ended 2017 and 2016, respectively:

	Weighted Average Inputs for the Period
	For the Years Ended
	December 31, 2017			December 31, 2016
Stock price	$	3.92		$	4.37
Exercise price	$	1.20		$	1.20
Contractual term (years)		0.78			1.15
Volatility (annual)		63	%		100	%
Risk-free rate		1	%		1	%
Dividend yield (per share)		0	%		0	%

The foregoing assumptions are recalculated every reporting period and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.

The following table presents changes in Level 3 warrant liabilities, reflected in accrued expenses measured at fair value for the year ended December 31, 2017 and 2016, respectively:

	Warrant
	Liability
Balance – January 1, 2016	$	26,493,000
Reclassification of derivative liabilities to equity at exercise date		(5,074,000)
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements		(15,465,000)
Change in fair value of warrant liability		(5,939,500)
Balance – December 31, 2016		14,500
Change in fair value of warrant liability		(5,500)
Balance – December 31, 2017	$	9,000

FAIR VALUE MEASUREMENTS

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

Note 7:

FAIR VALUE MEASUREMENTS

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:

Fair value measured at December 31, 2017

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

December 31, 2017

Warrant liability

9,000

Fair value measured at December 31, 2016

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

December 31, 2016

Warrant liability

14,500

There were no transfers between Level 1, 2 or 3 during the year ended December 31, 2017 and 2016, respectively.

The valuation of warrants is subjective and is affected by changes in inputs to the valuation model including the price per share of common stock, the historical volatility of the stock price, risk-free rates based on U. S. Treasury security yields, the expected term of the warrants and dividend yield. Changes in these assumptions can materially affect the fair value estimate. The Company could ultimately incur amounts to settle the warrant at a cash settlement value that is significantly different than the carrying value of the liability on the financial statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes in the fair value of the common stock warrants liability are recognized as a component of other income (expense) in the Statements of Operations.

The net cash settlement value at the time of any future transactions, where the Company consolidates or merges with another entity, will depend upon the value of the following inputs at that time: the consideration value per share of the Company’s common stock, the volatility of the Company’s common stock, the remaining term of the warrant from announcement date, the risk-free interest rate based on U. S. Treasury security yields, and the Company’s dividend yield. The warrant requires use of a volatility assumption equal to the greater of 100% and the 100-day volatility function determined as of the trading day immediately following announcement of a Fundamental Transaction.

Warrant Amendment Transaction

On August 10, 2016, the Company and holders of an aggregate of 3,096,665 outstanding Series A Warrants, Series A-1 Warrants, Series C Warrants, Series C-1 Warrants, Series D Warrants, Series D-1 Warrants, Series E Warrants and Series E-1 Warrants entered into warrant amendment agreements (the “Amended Warrants”) in which they agreed to amend the terms of the outstanding series warrants to remove provisions that had previously precluded equity classification treatment on the Company’s balance sheets.

The fair value of the Amended Warrants was re-measured immediately prior to the date of amendment with changes in fair value recorded as a gain of $5.1 million in the statement of operations and $15.5 million was reclassified to equity.

STOCKHOLDERS’ EQUITY

12 Months Ended

Dec. 31, 2017

Stockholders' Equity Note [Abstract]

STOCKHOLDERS’ EQUITY

Note 8:

stockholders’ equity

Preferred Stock

The Company has authorized up to 5,000,000 shares of preferred stock, $0.0001 par value per share, for issuance. The preferred stock will have such rights, privileges and restrictions, including voting rights, dividend conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company’s board of directors upon its issuance. To date, the Company has not issued any preferred shares.

Series A Preferred Stock - The Company has designated up to 1,250,000 shares of Series A Preferred Stock, $0.0001 par value per share, for issuance. To date, the Company has not issued any Series A preferred shares.

Series B Preferred Stock - The Company has designated up to 1,500,000 shares of Series B Preferred Stock, $0.0001 par value per share, for issuance. To date, the Company has not issued any Series B preferred shares.

Common Stock

The Company has authorized up to 41,666,667 shares of common stock, $0.0001 par value per share, for issuance. Significant 2017 and 2016 common stock transactions were as follows:

2017 Common Stock Transactions

June 2017 Private Placement Transaction

On June 26, 2017, the Company completed private placement of units with certain accredited investors. In the private placement transaction, the Company sold 1,503,567 shares of common stock for $3.97 per share and five-year warrants to purchase an equal number of shares of common stock, at an exercise price of $3.97 per share, for $0.125 per warrant, with one common share and one warrant being sold together as a unit for a total of $4.095 per unit. The Company issued and sold an aggregate of 1,503,567 units for aggregate gross proceeds of $6.2 million. The Company incurred $0.8 million in agency fees and legal costs. In connection with the offering, the Company reduced the exercise price for the warrants to purchase an aggregate of 653,187 shares of common stock issued to investors in the private placement that closed in August 2016 from $6.00 per share to $3.97 per share.

In addition, the Company issued five-year warrants to the placement agent in the offering providing for the purchase of up to 150,357 shares of Company common stock for $3.97 per share.

June 2017 Exercise and Repricing of Warrants Held by Existing Institutional Investors

On June 23, 2017, certain existing institutional shareholders of the Company who hold various outstanding warrants (i.e. C, D, E and F) to purchase Company common stock, entered into warrant repricing and exercise agreements.

Series E repriced and exercised warrants

Approximately 168,000 of Series E warrants were repriced from $15.00 per share to $3.97 per share and exercised immediately for gross proceeds of approximately $0.7 million. Series E warrants to purchase approximately 187,000 shares of Company common stock being reduced from $15.00 per share to $4.50 per share.

Series C, D & F repriced warrants

Additionally, the exercise prices for certain investors of Series C, Series D and Series F warrants were reduced as follows:

Series	Number of Warrant Shares Repriced		Pre-reduced Price		Post-reduced Price
Series C		313,750	$	6.00	$	4.00
Series D		312,500	$	9.00	$	4.00
Series F		292,500	$	7.20	$	4.00

The fair value relating to the modification of exercise prices on the repriced warrants was treated as deemed dividend on the statement of stockholders’ equity of $0.6 million.

	Before			After
	Modification			Modification
Exercise price	$	8.32		$	4.04
Contractual term (years)		3.34			3.34
Volatility (annual)		200	%		200	%
Risk-free rate		2	%		2	%
Dividend yield (per share)		0	%		0	%

2017 Management Compensation

On March 9, 2017, the Company issued 12,761 shares of stock to Dr. Glynn Wilson. The fair value of the common stock of $55,000 was recognized as stock-based compensation in general and administrative expenses. The issuance was based on the closing price or our common stock of $4.31 per share.

On March 9, 2017, the Company issued 5,220 shares of stock to our former Chief Operating Officer. The fair value of the common stock of $22,500 was recognized as stock-based compensation in general and administrative expenses. The issuance was based on the closing price or our common stock of $4.31 per share.

On September 22, 2017, the Company granted Mr. Hoang 250,000 shares of unregistered, fully vested restricted common stock. The Company recorded $0.8 million of stock-based compensation based on the fair value of the common stock at September 22, 2017. 70,289 shares of common stock, with a fair value of $0.2 million, were withheld (at the closing price of the Company's common stock on the NASDAQ Capital Market on September 22, 2017) to satisfy certain payroll liabilities, as applicable to the award.

On September 22, 2017, the Company granted Dr. Wilson 100,000 shares of unregistered, fully vested restricted common stock. The Company recorded $0.3 million of stock-based compensation based on the fair value of the common stock at September 22, 2017. 27,350 shares of common stock, with a fair value of $0.1 million, were withheld (at the closing price of the Company's common stock on the NASDAQ Capital Market on September 22, 2017) to satisfy certain payroll liabilities, as applicable to the award.

Consulting Arrangements

During fiscal 2017, the Company issued 0.2 million shares of common stock as part of consulting agreements. The fair value of the common stock of $0.6 million was recognized as stock-based compensation in general and administrative expenses.

2016 Common Stock Transactions

Private placements

On August 10, 2016 and August 25, 2016, the Company completed private placements of units with certain accredited investors. The units consisted of (i) one share of the Company’s common stock, par value $0.001 per share and (ii) one five-year warrant to purchase one share of Company common stock for $6.00. The Company issued and sold an aggregate of 653,187 units at a purchase price per unit of $4.80 for an aggregate of approximately $3.1 million. The Company incurred approximately $0.8 million in agency fees and legal costs.

Warrant Amendment Transaction

On August 10, 2016, the Company and holders of outstanding Series A Warrants, Series A-1 Warrants, Series C Warrants, Series C-1 Warrants, Series D Warrants, Series D-1 Warrants, Series E Warrants and Series E-1 Warrants entered into warrant amendment agreements in which they agreed to amend the terms of the outstanding series warrants to remove provisions that had previously precluded equity classification treatment on the Company’s balance sheets.

In consideration for such amendment and the exercise of the Series C Warrants and Series C-1 Warrants, the Company issued an aggregate of 750,000 additional shares of common stock to such warrant holders and new five-year warrants to purchase 1,000,000 shares of Company common stock at an exercise price of $7.20 per share.

Warrant Exercises

On August 11, 2016, holders of an aggregate of 583,333 outstanding Series C Warrants and 416,667 Series C-1 Warrants, each providing for the purchase of one share of our common stock for $6.00 per share, exercised their warrants for an aggregate exercise price of $6,000,000.

Exercise of Stock Options

In December 2016, Dr. John Bonfiglio exercised 10,417 shares of common stock pursuant to stock options at an exercise price equal to $1.74 per share.

Debt Settlement

In May 2016, the Company issued 10,191 common shares as part of debt conversion agreements from 2014. The fair value of the common stock of approximately $70,000 was recognized as loss on debt settlement agreements in other income (expense).

2016 Management Compensation

In July 2016, the Company entered into an employment agreement with Dr. John Bonfiglio relating to his appointment as the Company’s President and Chief Operating Officer. As part of the agreement, Dr. John Bonfiglio was awarded 20,833 common shares, which will vest upon the earlier of (i) the listing of the Company’s common stock on a national securities exchange in the United States or (ii) the first anniversary of the employment agreement, so long as Dr. John Bonfiglio is employed with the Company. The fair value of the common stock of approximately $103,000 was recognized as stock-based compensation in general and administrative expense.

Consulting arrangements

During the year ended December 31, 2016, the Company issued 75,000 common shares as part of consulting agreements. The fair value of the common stock of approximately $480,000 was recognized as stock-based compensation in general and administrative expense.

WARRANTS

12 Months Ended

Dec. 31, 2017

Warrants Disclosure [Abstract]

WARRANTS

Note 9:

WARRANTS

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of December 31, 2017 and 2016, respectively, and changes during the period is presented below:

					Weighted Average
	Number of		Weighted Average		Remaining Contractual		Total Intrinsic
	Warrants		Exercise Price		Life (in years)		Value
Balance - January 1, 2016		4,343,000		8.67		4.24	$	5,547,000
Issued		1,718,000		6.65		-		-
Exercised		(1,000,000)		6.00		-		-
Expired		(2,000)		287.20		-		-
Balance - December 31, 2016		5,059,000	$	8.49		3.68	$	1,713,000
Issued		1,654,000		3.97		-		-
Exercised		(168,000)		15.00		-		-
Expired		(25,000)		30.50		-		-
Balance - December 31, 2017		6,520,000	$	6.11		3.16	$	1,739,000

The following table reflects the status of the outstanding warrants at December 31, 2017:

Series	Total Outstanding Warrants		Exercise Price		Expiration
A		214,433	$	1.20	1/13/2020
C		313,749	$	4.00	1/13/2020
C		110,683	$	6.00	1/13/2020
D		312,501	$	4.00	Between 07/16/2020 and 08/13/2020 and 08/19/2020 and 09/09/2020
D		297,499	$	9.00	Between 07/16/2020 and 08/13/2020 and 08/19/2020 and 09/09/2020
E		186,557	$	4.50	Between 10/01/2020 and 11/12/2020 and 11/30/2020 and 12/09/2020
E		261,616	$	15.00	Between 10/01/2020 and 11/12/2020 and 11/30/2020 and 12/09/2020
F		292,499	$	4.00	8/11/2021
F		290,834	$	7.20	8/11/2021
A-1		418,750	$	1.20	3/9/2020
C-1		2,083	$	6.00	1/13/2020
D-1		416,667	$	9.00	Between 08/19/2020 and 09/09/2020
E-1		418,750	$	15.00	6/16/2020
F-1		416,667	$	7.20	8/11/2021
PIPE Warrants		653,187	$	3.97	8/11/2021
PIPE Warrants		1,503,567	$	3.97	6/22/2022
Broker Warrants		65,326	$	4.80	8/11/2021
Broker Warrants		150,357	$	3.97	6/22/2022
Other		194,796		$1.20 - $120.00	Between 4/04/2018 and 9/01/2019

2017 Warrant Transactions

June 2017 Private Placement Transaction

June 2017 Exercise and Repricing of Warrants Held by Existing Institutional Investors

Series E repriced and exercised warrants

Series C, D & F repriced warrants

Additionally, the exercise prices for certain investors of Series C, Series D and Series F warrants were reduced as follows:

	Number of
	Warrant Shares		Pre-reduced		Post-reduced
Series	Repriced		Price		Price
Series C		313,750	$	6.00	$	4.00
Series D		312,500	$	9.00	$	4.00
Series F		292,500	$	7.20	$	4.00

The fair value relating to the modification of exercise prices on the repriced warrants was treated as deemed dividend on the statement of stockholders’ equity of $0.6 million.

June 2017 Agent Warrants

Pursuant to an agency agreement, dated May 12, 2017, by and between Katalyst Securities LLC and us, Katalyst agreed to act as our placement agent in connection with the June 26, 2017 private placement offering.

Pursuant to the agreement, we agreed to pay to Katalyst: (i) an aggregate cash fee for placement agent and financial advisory services equal to 10% of the gross proceeds of the Offering; (ii) a non-accountable expense allowance in the amount of Seventy Thousand Dollars ($70,000); and (iii) five-year warrants to purchase a number of shares of our common stock equal to 10% of the number of shares sold in the offering. The Katalyst Warrants have the same terms as the private placement warrants issued in the offering. Based on the 1,503,567 shares of common stock sold in the private placement, we issued five-year warrants to Katalyst providing for the purchase of up to 150,357 shares of Company common stock for $3.97 per share.

2016 Warrant Transactions

August 2016 Warrant Exercises

August 2016 Warrant Amendments

As discussed in Note 8, Stockholders’ Equity, simultaneous with the exercise of the warrants, the Company and holders of outstanding Series A Warrants, Series A-1 Warrants, Series C Warrants, Series C-1 Warrants, Series D Warrants, Series D-1 Warrants, Series E Warrants and Series E-1 Warrants entered into warrant amendment agreements, in which they agreed to amend the terms of the existing warrant agreements to remove provisions that had previously caused them to be classified as a derivative liability as opposed to equity on our balance sheet. In consideration for such amendment and the exercise of the Series C Warrants and Series C-1 Warrants, we issued an aggregate of 750,000 additional shares of common stock to such warrant holders and new five-year warrants to purchase 1,000,000 shares of our common stock at an exercise price of $7.20 per share (the “Series F and F-1Warrants”). The value of the shares and fair value of the warrants was treated as dividend on the statement of stockholders’ equity of $4.5 million.

August 2016 Private Placement Transaction

In addition, the Company issued five-year warrants to the placement agent in the offering providing for the purchase of up to 65,317 shares of Company common stock for $4.80 per share.

STOCK OPTION PLANS

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK OPTION PLANS

Note 10:

stock OPTION PLANS

Options to Purchase Shares of Common Stock

2014 Stock Omnibus Plan

On March 19, 2014, the Board adopted the 2014 Omnibus Stock Option Plan (“2014 Plan”), which replaced the 2009 Stock Incentive Plan. The 2014 Plan allowed for grants of stock options, restricted shares, stock bonuses and other equity based awards to employees and non-employee directors of the Company. Awards under the 2014 Plan may be at prices and for terms as determined by the Board of Directors, and may have vesting requirements as determined by the Board, provided that the exercise price for any stock option must be at least equal to the fair market value (as defined in the 2014 Plan) of a share of the stock on the grant date. Once granted, the exercise price of an option may not be reduced without the approval of the Company’s stockholders, other than under certain limited circumstances such as a stock split, or take any other action with respect to a stock option that would be treated as a repricing under the rules and regulations of the New York Stock Exchange.

The 2014 Plan was amended in February 2015 to provide for grants to consultants, and again in November 2015 to (i) increase the number of shares reserved for issuance under the Plan to 0.6 million shares; (ii) provide the Board and Committee administering the Plan with full discretion on the vesting period for Service-Vesting Awards under the Plan, including the grant of Awards with less than the Minimum Vesting Requirement (as such terms are defined in the Plan), and (iii) provide the Board and Committee administering the Plan with the ability to grant stock bonuses to executive officers.

On August 29, 2017, the 2014 Plan was amended to increase the shares reserved under the Plan to 1.4 million shares. As of December 31, 2017, approximately 533,000 options are available to be issued from the 2014 Plan.

Stock Options

A summary of the Company’s stock option activity is as follows for stock options:

	Number of Shares		Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding as of January 1, 2016		298,679	$	9.22	$	177,000		9.7
Granted		147,500		5.84		-		9.3
Exercised		(10,417)		1.74		-		-
Forfeited/expired		(1,667)		228.00		-		-
Outstanding as of December 31, 2016		434,095		7.41		39,000		8.9
Granted		90,000		3.18		-		9.7
Forfeited/expired		(34,840)		6.75		-		-
Outstanding as of December 31, 2017		489,255	$	6.68	$	107,000		8.3
Options vested and exercisable		385,760	$	7.44	$	41,000		8.0

The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company’s share-based compensation plans. The weighted average assumptions used in calculating the fair values of stock options that were granted during the years ended December 31, 2017, 2016, respectively, were as follows:

	For the Years Ended
	December 31,
	2017			2016
Exercise price	$	3.25		$	5.84
Expected term (years)		10.0			9.7
Expected stock price volatility		217	%		238	%
Risk-free rate of interest		2	%		2	%
Expected dividend rate		0	%		0	%

The Company recorded $2.6 million and $1.6 million of stock-based compensation expense to general and administrative expenses for the years ended December 31, 2017 and 2016, respectively. The Company recorded $0.1 million of stock-based compensation expense to research and development for the year ended December 31, 2017.

Unrecognized stock-based compensation cost:	$	262,000

Expected weighted average period compensation costs to be recognized (years):		0.7

GRANT INCOME

12 Months Ended

Dec. 31, 2017

Text Block [Abstract]

GRANT INCOME

Note 11:

grant income

During the years ended December 31, 2017 and 2016, the Company received $0.2 million of a grant awarded to Mayo Foundation from the U.S. Department of Defense for the Phase II Clinical Trial of TPIV200. The grant compensated the Company for clinical supplies manufactured and provided by the Company for the clinical study.

CONTINGENCIES AND COMMITMENTS

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

CONTINGENCIES AND COMMITMENTS

Note 12:

ContingencIES AND COMMITMENTs

Employment Agreements

On August 25, 2016, the Company appointed Michael J. Loiacono as the Company’s Chief Financial Officer, Chief Accounting Officer, Secretary and Treasurer. In connection with Mr. Loiacono’s appointment, he entered into an employment agreement with the Company. The employment agreement provides that Mr. Loiacono’s base salary will be $200,000 per year and he is eligible for an annual performance bonus of up to 50% of his base salary. The term of the employment agreement is for two years and will be automatically extended for an additional 12 months unless terminated by Mr. Loiacono or the Company.

On September 22, 2017, the Company appointed Peter Hoang as the Company’s President and Chief Executive Officer. In connection with Mr. Hoang’s appointment, he entered into an employment agreement with the Company. The employment agreement provides that Mr. Hoang’s base salary will be $362,500 per year and he is eligible for an annual performance bonus of up to 50% of his base salary. In addition, on the first anniversary of the employment agreement, Mr. Hoang will be eligible to receive a grant of stock options to purchase the number of shares of common stock equal to one percent of the then-outstanding common stock of the Company. The term of the employment agreement is for three years and will be automatically extended for an additional 12 months unless terminated by Mr. Hoang or the Company.

On September 22, 2017, the Company entered into an amended employment agreement with Dr. Glynn Wilson, the Company’s Strategic Advisor. The amended employment agreement provides that Dr. Wilson’s base salary will be $205,000 per year and he is eligible for an annual performance bonus of up to 50% of his base salary. In addition, upon the first anniversary of the execution of amendment employment agreement, Dr. Wilson will be eligible to receive an additional grant of restricted common stock equal to $300,000. The term of the employment agreement is through December 31, 2018.

Operating Lease Obligations

The Company was a party to several operating leases as of December 31, 2017, primarily for office space at certain locations.

Future minimum lease payments under the Company’s operating leases as of December 31, 2017, for each of the next five years and thereafter are as following (rounded to nearest thousand):

2018	$	116,000
2019		108,000
2020		111,000
2021		114,000
2022		68,000
Thereafter		-
Total	$	517,000

Total rental expense under the Company’s operating leases was $121,200 and $82,500 for the years ended December 31, 2017 and 2016, respectively.

LEGAL PROCEEDINGS

12 Months Ended

Dec. 31, 2017

Disclosure Text Block Supplement [Abstract]

LEGAL PROCEEDINGS

Note 13:

LEGAL PROCEEDINGS

From time to time, the Company may be party to ordinary, routine litigation incidental to their business. The Company knows of no material, active or pending legal proceedings against the Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of the Company’s directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to the Company’s interest. The Company was not involved in any litigation during the years ended December 31, 2017 and 2016.

INCOME TAXES

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 14:

INCOME TAXES

The Company has no income tax expense due to operating losses incurred for the years ended December 31, 2017 and 2016. Approximately $62,000 in non-qualified stock options were cancelled during 2017 due to terminations that resulted in a reversal of the deferred tax asset of approximately $16,000. The cancellations did not result in a book income for December 31, 2017.

The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December 31, 2017 and 2016 are as follows:

	For the years ended
	December 31,
	2017		2016
Deferred tax assets:
Net operating loss carryforward	$	13,653,000	$	10,934,000
Stock-based compensation		2,231,000		2,066,000
License agreements		493,000		490,000
Research and development		117,000		117,000
Technology licensing fee		185,000		185,000
Valuation allowance		(16,679,000)		(13,792,000)
Deferred tax assets, net of valuation allowance	$	-	$	-

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”), which makes broad and complex changes to the U.S. tax code. Certain of these changes may be applicable to the Company, including but not limited to, reducing the U.S. federal corporate tax rate from 35 percent to 21 percent, creating a new limitation on deductible interest expense, eliminating the corporate alternative minimum tax (“AMT”), modifying the rules related to uses and limitations of net operating loss carryforwards generated in tax years ending after December 31, 2017, and changing the rules pertaining to the taxation of profits earned abroad. Changes in tax rates and tax laws are accounted for in the period of enactment. The Tax Act reduces the corporate tax rate to 21 percent, effective January 1, 2018.

The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the history of losses, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized and has established a full valuation allowance for the years ended December 31, 2017 and 2016. Consequently, the deferred tax asset valuation allowance increased by $2.9 million as of December 31, 2017. The Company has research and development tax credit carryforwards of $117,000 to offset future federal income taxes. The research and development tax credit carryforwards begin to expire in 2029.

The Company has approximately $41.7 million of federal and $21.9 million of state Net Operating Loss (“NOL”s) that may be available to offset future taxable income, if any. The federal net operating loss carryforwards, if not utilized, will expire between 2029 and 2037. The state net operating loss carryforwards, if not utilized, will expire in 2037.

In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s net operating loss carryforwards may be limited in the event of a change in ownership. A full Section 382 analysis has not been prepared and NOLs could be subject to limitation under Section 382.

For the years ended December 31, 2017 and 2016, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:

	For the years ended
	December 31,
	2017		2016
U. S. federal statutory rate	$	(3,734,000)	$	(835,000)
State taxes, net of federal benefit		(414,000)		(286,000)
Federal tax rate change		1,401,000		-

Permanent differences
- Change in fair value of derivative liabilities		(2,000)		(2,019,000)
- Other permanent differences		(161,000)		46,000
Change in valuation allowance		2,890,000		2,966,000
Other		20,000		128,000
Income tax provision (benefit)	$	-	$	-

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December 31, 2017 and 2016, there were no unrecognized tax benefits. The Company recognizes accrued interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31, 2017 and 2016. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next year.

Upon completion of our 2017 U.S. income tax return in 2018 we may identify additional remeasurement adjustments to our recorded deferred tax liabilities and the one-time transition tax. We will continue to assess our provision for income taxes as future guidance is issued, but do not currently anticipate significant revisions will be necessary. Any such revisions will be treated in accordance with the measurement period guidance outlined in Staff Accounting Bulletin No. 118.

A reconciliation of the Company’s effective tax rate to the statutory U.S. federal rate is as follows:

	For the years ended
	December 31,
	2017			2016
U. S. federal statutory rate		(34.0)	%		(34.0)	%
State taxes, net of federal benefit		(3.6)	%		(11.6)	%
Federal tax rate change		12.3	%		0.0	%

Permanent differences
- Change in fair value of derivative liabilities		(0.0)	%		(82.2)	%
- Other permanent differences		(1.5)	%		1.9	%
Change in valuation allowance		26.3	%		120.8	%
Other		0.5	%		5.2	%
Income tax provision (benefit)		(0.0)	%		0.0	%

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

These financial statements are presented in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Principles of Consolidation

Principles of Consolidation

Use of Estimates

Use of Estimates

Liquidity, financial condition and managements plans

Liquidity, financial condition and managements plans

There is no certainty that the Company will be able to arrange sufficient funding to continue development of products to marketability.

Fair Value Measurements

Fair Value Measurements

•

Level 1 - Quoted prices (unadjusted) in active markets for identical assets and liabilities.

•

Patents and Patent Application Costs

Patents and Patent Application Costs

Stock-Based Compensation

Stock-Based Compensation

Expected Volatility — The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

Risk-Free Interest Rate — The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

Research and Development Costs

Research and Development Costs

The Company incurred costs of approximately $5.3 million and $3.8 million on research and development for the year ended December 31, 2017 and 2016, respectively.

Income Taxes

Income Taxes

Derivative Liability

Derivative Liability

Grant Income

Grant Income

Earnings (Loss) Per Common Share

Loss per Common Share

Cash and Credit Risk

Cash and Credit Risk

New Accounting Pronouncements

New Accounting Pronouncements

Recent Accounting Pronouncements Adopted in the Year

Going Concern

Deferred Taxes

Compensation-Stock Compensation

Statement of Cash Flows

Recent Accounting Pronouncements Not Yet Adopted

Accounting for Certain Financial Instruments with Down Round Features

Compensation-Stock Compensation

Revenue from Contracts with Customers

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables)

12 Months Ended

Dec. 31, 2017

Noncontrolling Interest [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of loss per share for the years ended December 31, 2017 and 2016, respectively:

	For the Years Ended
	December 31,
	2017		2016
Numerator:
Net loss	$	(10,982,177)	$	(2,455,381)
Less: non-cash income from change in fair value of common stock warrants		-		(2,856,000)
Net loss - diluted		(10,982,177)		(5,311,381)

Denominator:
Weighted average common shares outstanding - basic		9,453,483		6,889,898
Dilutive effect of warrants, net		-		531,097
Weighted average common shares outstanding - diluted		9,453,483		7,420,995

Net loss per share data:
Basic	$	(1.16)	$	(0.36)
Diluted	$	(1.16)	$	(0.72)

Net Loss Per Share

The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

	Year Ended
	December 31,
	2017		2016
Common stock options		489,000		432,000
Common Stock Purchase Warrants		6,521,000		5,060,000
Potentially dilutive securities		7,010,000		5,492,000

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)

12 Months Ended

Dec. 31, 2017

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consist of the following as of December 31, 2017 and 2016, respectively:

	December 31,		December 31,
	2017		2016
Accounts payable	$	1,015,000	$	680,000
Compensation and benefits		162,000		218,000
Professional fees		32,000		53,000
Consulting agreements		-		95,000
Technology license fees		105,000		105,000
Investor relations fees		110,000		-
Other		84,000		74,000
Total accounts payable and accrued liabilities	$	1,508,000	$	1,225,000

WARRANT LIABILITY (Tables)

12 Months Ended

Dec. 31, 2017

Warrant Liability [Abstract]

Valuation Methodology

	Weighted Average Inputs for the Period
	For the Years Ended
	December 31, 2017			December 31, 2016
Stock price	$	3.92		$	4.37
Exercise price	$	1.20		$	1.20
Contractual term (years)		0.78			1.15
Volatility (annual)		63	%		100	%
Risk-free rate		1	%		1	%
Dividend yield (per share)		0	%		0	%

Schedule of Changes in Level 3 Liabilities Measured at Fair Value

The following table presents changes in Level 3 warrant liabilities, reflected in accrued expenses measured at fair value for the year ended December 31, 2017 and 2016, respectively:

	Warrant
	Liability
Balance – January 1, 2016	$	26,493,000
Reclassification of derivative liabilities to equity at exercise date		(5,074,000)
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements		(15,465,000)
Change in fair value of warrant liability		(5,939,500)
Balance – December 31, 2016		14,500
Change in fair value of warrant liability		(5,500)
Balance – December 31, 2017	$	9,000

FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Financial Assets And Liabilities Measured At Fair Value On Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:

Fair value measured at December 31, 2017

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

December 31, 2017

Warrant liability

9,000

Fair value measured at December 31, 2016

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

December 31, 2016

Warrant liability

14,500

STOCKHOLDERS’ EQUITY (Tables)

12 Months Ended

Dec. 31, 2017

Stockholders' Equity Note [Abstract]

Schedule of warrants exercise prices were reduced

Additionally, the exercise prices for certain investors of Series C, Series D and Series F warrants were reduced as follows:

Series	Number of Warrant Shares Repriced		Pre-reduced Price		Post-reduced Price
Series C		313,750	$	6.00	$	4.00
Series D		312,500	$	9.00	$	4.00
Series F		292,500	$	7.20	$	4.00

Schedule of weighted average valuation methodology

	Before			After
	Modification			Modification
Exercise price	$	8.32		$	4.04
Contractual term (years)		3.34			3.34
Volatility (annual)		200	%		200	%
Risk-free rate		2	%		2	%
Dividend yield (per share)		0	%		0	%

WARRANTS (Tables)

12 Months Ended

Dec. 31, 2017

Schedule of warrants exercise prices were reduced

The following table reflects the status of the outstanding warrants at December 31, 2017:

Series	Total Outstanding Warrants		Exercise Price		Expiration
A		214,433	$	1.20	1/13/2020
C		313,749	$	4.00	1/13/2020
C		110,683	$	6.00	1/13/2020
D		312,501	$	4.00	Between 07/16/2020 and 08/13/2020 and 08/19/2020 and 09/09/2020
D		297,499	$	9.00	Between 07/16/2020 and 08/13/2020 and 08/19/2020 and 09/09/2020
E		186,557	$	4.50	Between 10/01/2020 and 11/12/2020 and 11/30/2020 and 12/09/2020
E		261,616	$	15.00	Between 10/01/2020 and 11/12/2020 and 11/30/2020 and 12/09/2020
F		292,499	$	4.00	8/11/2021
F		290,834	$	7.20	8/11/2021
A-1		418,750	$	1.20	3/9/2020
C-1		2,083	$	6.00	1/13/2020
D-1		416,667	$	9.00	Between 08/19/2020 and 09/09/2020
E-1		418,750	$	15.00	6/16/2020
F-1		416,667	$	7.20	8/11/2021
PIPE Warrants		653,187	$	3.97	8/11/2021
PIPE Warrants		1,503,567	$	3.97	6/22/2022
Broker Warrants		65,326	$	4.80	8/11/2021
Broker Warrants		150,357	$	3.97	6/22/2022
Other		194,796		$1.20 - $120.00	Between 4/04/2018 and 9/01/2019

Schedule of warrants exercise prices were reduced

Additionally, the exercise prices for certain investors of Series C, Series D and Series F warrants were reduced as follows:

Series	Number of Warrant Shares Repriced		Pre-reduced Price		Post-reduced Price
Series C		313,750	$	6.00	$	4.00
Series D		312,500	$	9.00	$	4.00
Series F		292,500	$	7.20	$	4.00

Warrant [Member]

Schedule of share purchase warrants

A summary of the Company’s share purchase warrants as of December 31, 2017 and 2016, respectively, and changes during the period is presented below:

					Weighted Average
	Number of		Weighted Average		Remaining Contractual		Total Intrinsic
	Warrants		Exercise Price		Life (in years)		Value
Balance - January 1, 2016		4,343,000		8.67		4.24	$	5,547,000
Issued		1,718,000		6.65		-		-
Exercised		(1,000,000)		6.00		-		-
Expired		(2,000)		287.20		-		-
Balance - December 31, 2016		5,059,000	$	8.49		3.68	$	1,713,000
Issued		1,654,000		3.97		-		-
Exercised		(168,000)		15.00		-		-
Expired		(25,000)		30.50		-		-
Balance - December 31, 2017		6,520,000	$	6.11		3.16	$	1,739,000

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

STOCK OPTION PLANS (Tables)

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Compensation, Activity

A summary of the Company’s stock option activity is as follows for stock options:

	Number of Shares		Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding as of January 1, 2016		298,679	$	9.22	$	177,000		9.7
Granted		147,500		5.84		-		9.3
Exercised		(10,417)		1.74		-		-
Forfeited/expired		(1,667)		228.00		-		-
Outstanding as of December 31, 2016		434,095		7.41		39,000		8.9
Granted		90,000		3.18		-		9.7
Forfeited/expired		(34,840)		6.75		-		-
Outstanding as of December 31, 2017		489,255	$	6.68	$	107,000		8.3
Options vested and exercisable		385,760	$	7.44	$	41,000		8.0

Schedule or Description of Weighted Average Discount Rate

	For the Years Ended
	December 31,
	2017			2016
Exercise price	$	3.25		$	5.84
Expected term (years)		10.0			9.7
Expected stock price volatility		217	%		238	%
Risk-free rate of interest		2	%		2	%
Expected dividend rate		0	%		0	%

Schedule of Unrecognized Compensation Cost, Nonvested Awards

Unrecognized stock-based compensation cost:	$	262,000

Expected weighted average period compensation costs to be recognized (years):		0.7

CONTINGENCIES AND COMMITMENTS (Tables)

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

Future minimum lease payments under the Company’s operating leases as of December 31, 2017, for each of the next five years and thereafter are as following (rounded to nearest thousand):

2018	$	116,000
2019		108,000
2020		111,000
2021		114,000
2022		68,000
Thereafter		-
Total	$	517,000

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Schedule of Deferred Tax Assets and Liabilities

The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December 31, 2017 and 2016 are as follows:

	For the years ended
	December 31,
	2017		2016
Deferred tax assets:
Net operating loss carryforward	$	13,653,000	$	10,934,000
Stock-based compensation		2,231,000		2,066,000
License agreements		493,000		490,000
Research and development		117,000		117,000
Technology licensing fee		185,000		185,000
Valuation allowance		(16,679,000)		(13,792,000)
Deferred tax assets, net of valuation allowance	$	-	$	-

Summary Of Expected Tax Expense Benefit Based On Federal Statutory Rates Reconciled With Actual Tax Provision Benefit

For the years ended December 31, 2017 and 2016, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:

	For the years ended
	December 31,
	2017		2016
U. S. federal statutory rate	$	(3,734,000)	$	(835,000)
State taxes, net of federal benefit		(414,000)		(286,000)
Federal tax rate change		1,401,000		-

Permanent differences
- Change in fair value of derivative liabilities		(2,000)		(2,019,000)
- Other permanent differences		(161,000)		46,000
Change in valuation allowance		2,890,000		2,966,000
Other		20,000		128,000
Income tax provision (benefit)	$	-	$	-

Schedule of Effective Income Tax Rate Reconciliation

A reconciliation of the Company’s effective tax rate to the statutory U.S. federal rate is as follows:

	For the years ended
	December 31,
	2017			2016
U. S. federal statutory rate		(34.0)	%		(34.0)	%
State taxes, net of federal benefit		(3.6)	%		(11.6)	%
Federal tax rate change		12.3	%		0.0	%

Permanent differences
- Change in fair value of derivative liabilities		(0.0)	%		(82.2)	%
- Other permanent differences		(1.5)	%		1.9	%
Change in valuation allowance		26.3	%		120.8	%
Other		0.5	%		5.2	%
Income tax provision (benefit)		(0.0)	%		0.0	%

NATURE OF OPERATIONS - Additional Information (Detail)	12 Months Ended
NATURE OF OPERATIONS - Additional Information (Detail)	Dec. 31, 2017 Patient
Number of ovarian cancer patients	30,000
Percentage of breast cancers	50.00%
Percentage of ovarian cancers	95.00%

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Research and Development Expense	$ 5,250,985	$ 3,800,035
Cash, FDIC Insured Amount	250,000
Cash, Uninsured Amount	$ 4,900,000	$ 7,600,000

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER - Computation of income (loss) per share (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Numerator:
Net loss	$ (10,982,177)	$ (2,455,381)
Less: non-cash income from change in fair value of common stock warrants	0	(2,856,000)
Net loss - diluted	$ (10,982,177)	$ (5,311,381)
Denominator:
Weighted average common shares outstanding - basic	9,453,483	6,889,898
Dilutive effect of warrants, net	0	531,097
Weighted average common shares outstanding - diluted	9,453,483	7,420,995
Net loss per share data:
Basic	$ (1.16)	$ (0.36)
Diluted	$ (1.16)	$ (0.72)

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER - Potentially Dilutive Securities (Detail) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Common stock options	489,000	432,000
Common Stock Purchase Warrants	6,521,000	5,060,000
Potentially dilutive securities	7,010,000	5,492,000

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES -Accounts payable and accrued liabilities (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Accounts Payable And Accrued Liabilities [Line Items]
Accounts payable	$ 1,015,000	$ 680,000
Compensation and benefits	162,000	218,000
Professional fees	32,000	53,000
Consulting agreements	0	95,000
Technology license fees	105,000	105,000
Investor relations fees	110,000	0
Other	84,000	74,000
Total accounts payable and accrued liabilities	$ 1,508,312	$ 1,224,940

RESEARCH AGREEMENT OBLIGATIONS - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	May 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Gain (Loss) on Extinguishment of Debt	$ 70,000	$ 492,365	$ 0
Crucell Holland Bv [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Accrued Liabilities		500,000
Debt Instrument, Increase (Decrease), Net		0
Gain (Loss) on Extinguishment of Debt		$ 500,000

WARRANT LIABILITY - Conversion Option - Valuation Methodology (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price	$ 3.92	$ 4.37
Share Purchase Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price	$ 1.2	$ 1.2
Contractual term (years)	9 months 11 days	1 year 1 month 24 days
Volatility (annual)	63.00%	100.00%
Risk-free rate	1.00%	1.00%
Dividend yield (per share)	0.00%	0.00%

WARRANT LIABILITY - Conversion Option - Schedule of Changes in Level 3 Liabilities Reflected in Accrued Expenses Measured at Fair Value (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Class of Warrant or Right [Line Items]
Balance	$ 14,500	$ 26,493,000
Reclassification of derivative liabilities to equity at exercise date		(5,074,000)
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements		(15,465,000)
Change in fair value of warrant liability	(5,500)	(5,939,500)
Balance	$ 9,000	$ 14,500

FAIR VALUE MEASUREMENTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Quoted prices in active markets (Level 1)
Derivatives, Fair Value [Line Items]
Warrant liability	$ 0	$ 0
Significant other observable inputs (Level 2)
Derivatives, Fair Value [Line Items]
Warrant liability	0	0
Significant other observable inputs (Level 3)
Derivatives, Fair Value [Line Items]
Warrant liability	9,000	14,500
Fair Value [Member]
Derivatives, Fair Value [Line Items]
Warrant liability	$ 9,000	$ 14,500

FAIR VALUE MEASUREMENTS - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Aug. 10, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Outstanding	6,520,000	5,059,000	3,096,665	4,343,000
Derivative, Gain on Derivative	$ 5.1
Fair Value Of Warrant Reclassification To Equity	$ 15.5

STOCKHOLDERS' EQUITY - Summary of number of price-reduced and price-retained warrants (Detail)	Dec. 31, 2017 $ / shares shares
Number of Warrant Shares Repriced [Member] \| Series C Warrant [Member]
Class of Warrant or Right [Line Items]
Number of Warrant Shares \| shares	313,750
Number of Warrant Shares Repriced [Member] \| Series D Warrant [Member]
Class of Warrant or Right [Line Items]
Number of Warrant Shares \| shares	312,500
Number of Warrant Shares Repriced [Member] \| Series F Warrant [Member]
Class of Warrant or Right [Line Items]
Number of Warrant Shares \| shares	292,500
Pre-reduced Price [Member] \| Series C Warrant [Member]
Class of Warrant or Right [Line Items]
Price	$ 6.00
Pre-reduced Price [Member] \| Series D Warrant [Member]
Class of Warrant or Right [Line Items]
Price	9.00
Pre-reduced Price [Member] \| Series F Warrant [Member]
Class of Warrant or Right [Line Items]
Price	7.20
Post-reduced Price [Member] \| Series C Warrant [Member]
Class of Warrant or Right [Line Items]
Price	4.00
Post-reduced Price [Member] \| Series D Warrant [Member]
Class of Warrant or Right [Line Items]
Price	4.00
Post-reduced Price [Member] \| Series F Warrant [Member]
Class of Warrant or Right [Line Items]
Price	$ 4.00

STOCKHOLDERS' EQUITY - Conversion Option - Valuation Methodology (Detail) - Share Purchase Warrants [Member]	12 Months Ended
	Dec. 31, 2017 $ / shares
Weighted Average Inputs Before Modification [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price	$ 8.32
Contractual term (years)	3 years 4 months 2 days
Volatility (annual)	200.00%
Risk-free rate	2.00%
Dividend yield (per share)	0.00%
Weighted Average Inputs After Modification [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price	$ 4.04
Contractual term (years)	3 years 4 months 2 days
Volatility (annual)	200.00%
Risk-free rate	2.00%
Dividend yield (per share)	0.00%

STOCKHOLDERS’ EQUITY - Additional Information (Detail)			1 Months Ended							12 Months Ended
STOCKHOLDERS’ EQUITY - Additional Information (Detail)	May 09, 2017 USD ($) $ / shares shares	Aug. 11, 2016 USD ($) $ / shares shares	Sep. 22, 2017 USD ($) shares	Jun. 26, 2017 $ / shares $ / PerUnit shares	Jun. 23, 2017 USD ($) $ / shares shares	Aug. 31, 2016 USD ($) $ / shares shares	Aug. 25, 2016 USD ($) $ / shares $ / PerUnit shares	Jul. 31, 2016 USD ($) shares	May 31, 2016 USD ($) shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Aug. 10, 2016 $ / shares shares	Dec. 31, 2015 shares
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Fair value of common stock \| $								$ 103,000
Common shares issued									10,191
Common Stock, Par or Stated Value Per Share \| $ / shares										$ 0.001	$ 0.001
Share-based Compensation \| $										$ 2,738,244	$ 1,558,409
Gain (Loss) on Extinguishment of Debt \| $									$ 70,000	$ 492,365	$ 0
Class of Warrant or Right, Outstanding										6,520,000	5,059,000	3,096,665	4,343,000
Preferred Stock, Shares Authorized										5,000,000	5,000,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares										$ 0.001	$ 0.001
Common Stock, Shares Authorized										41,700,000	41,700,000
Proceeds from Warrant Exercises \| $										$ 619,623	$ 5,483,349
Share Price \| $ / shares										$ 3.92	$ 4.37
Exercise Of Warrants Amount \| $										$ 666,666	$ 5,483,349
Series C1 Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares		$ 6.00								$ 4.00		$ 7.20
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												1,000,000
Class of Warrant or Right, Outstanding		416,667								313,749
Stock Issued During Period Shares, Upon Exercise Of Warrants		750,000
Proceeds from Warrant Exercises \| $		$ 6,000,000
Subsequent Warrant Issuance [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 3.97	$ 3.97
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right					150,357
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				150,357
Series C-1 Warrants [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Outstanding		416,667
Class Of Warrant Or Right trancheTwo [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares					$ 4.50
Class Of Warrant Or Right tranche One [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares					15.00
Series A Preferred Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Preferred Stock, Shares Authorized										1,250,000	1,250,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares										$ 0.001	$ 0.001
Series B Preferred Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Preferred Stock, Shares Authorized										1,500,000	1,500,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares										$ 0.001	$ 0.001
Unregistered Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period								20,833
Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Exercise Of Warrants Amount \| $										$ 600,000
Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period											10,417
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares											$ 1.74
Stock Issued During Period, Shares, Share-based Compensation, Gross										620,685	114,435
Exercise Of Warrants Amount \| $										$ 168	$ 1,000
Private Placement [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Common Stock, Par or Stated Value Per Share \| $ / shares						$ 3.97	$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 3.97	$ 15.00	$ 6.00	$ 6.00			$ 3.97
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right					168,000
Legal Fees \| $						$ 800,000	$ 800,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				653,187
Number Of Equity Unit Issued						1,503,567
Equity Unit Issued Price Per Unit \| $ / PerUnit				4.095			4.80
Aggregate Purchase Price Of Shares Agreed To Purchase Under Stock Purchases Agreement \| $						$ 6,200,000
Class of Warrant or Right, Outstanding							65,317
Proceeds from Warrant Exercises \| $					$ 700,000
Number Of Units Sold				1,503,567	1,503,567
Class Of Warrant Or Right Warrant Price \| $ / shares				$ 0.125
Private Placement [Member] \| Class Of Warrant Or Right tranche One [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right					187,000
Consulting Agreements [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Fair value of common stock \| $										$ 200,000	$ 75,000
Common shares issued										600,000	480,000
Chief Executive Officer, President and Chairman [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Stock Issued During Period, Value, Share-based Compensation, Gross \| $	$ 55,000
Share Price \| $ / shares	$ 4.31
Stock Issued During Period, Shares, Share-based Compensation, Gross	12,761
Chief Operating Officer [Member] \| Unregistered Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Share-based Compensation \| $			$ 800,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			250,000
Share Based Compensation Arrangement By Share Based Payment Awards Equity Instruments Other Than Options With held			70,289
Share Based Compensation Arrangement By Share Based Payment Awards Equity Instruments Other Than Options Fair Value Of Instruments With held \| $			$ 200,000
Dr Glynn Wilson [Member] \| Unregistered Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Share-based Compensation \| $			$ 300,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			100,000
Share Based Compensation Arrangement By Share Based Payment Awards Equity Instruments Other Than Options With held			27,350
Share Based Compensation Arrangement By Share Based Payment Awards Equity Instruments Other Than Options Fair Value Of Instruments With held \| $			$ 100,000
President And Chief Operating Officer [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Stock Issued During Period, Value, Share-based Compensation, Gross \| $	$ 22,500
Share Price \| $ / shares	$ 4.31
Stock Issued During Period, Shares, Share-based Compensation, Gross	5,220

WARRANTS - Share Purchase Warrants (Detail) - USD ($)	12 Months Ended
WARRANTS - Share Purchase Warrants (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Number of Warrants, Beginning balance	5,059,000	4,343,000
Number of Warrants, Issued	1,654,000	1,718,000
Number of Warrants, Exercised	(168,000)	(1,000,000)
Number of Warrants, Extinguished or expired	(25,000)	(2,000)
Number of Warrants, Ending balance	6,520,000	5,059,000	4,343,000
Weighted Average Exercise Price, Beginning Balance	$ 8.49	$ 8.67
Weighted Average Exercise Price, Issued	3.97	6.65
Weighted Average Exercise Price, Exercised	15	6
Weighted Average Exercise Price, Extinguished or expired	30.5	287.2
Weighted Average Exercise Price, Ending Balance	$ 6.11	$ 8.49	$ 8.67
Weighted Average Remaining Contractual Life, Outstanding (in years)	3 years 1 month 28 days	3 years 8 months 5 days	4 years 2 months 26 days
Weighted Average Remaining Contractual Life, Issued (in years)	0 years	0 years
Total Intrinsic Value, Beginning balance	$ 1,713,000	$ 5,547,000
Total Intrinsic Value, Ending balance	$ 1,739,000	$ 1,713,000	$ 5,547,000

WARRANTS-Amendment Agreement and private placement (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Aug. 11, 2016	Aug. 10, 2016	Dec. 31, 2015
Class of Warrant or Right, Outstanding	6,520,000	5,059,000		3,096,665	4,343,000
Series A1 Warrant [Member]
Class of Warrant or Right, Outstanding	214,433
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.20
Class Of Warrant Or Right expiration Date	1/13/2020
Series C1 Warrant [Member]
Class of Warrant or Right, Outstanding	313,749		416,667
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.00		$ 6.00	$ 7.20
Class Of Warrant Or Right expiration Date	1/13/2020
Series D1 Warrant [Member]
Class of Warrant or Right, Outstanding	312,501
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.00
Class Of Warrant Or Right expiration Date	Between 07/16/2020 and 08/13/2020 and 08/19/2020 and 09/09/2020
Series D2 warrant [Member]
Class of Warrant or Right, Outstanding	297,499
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.00
Class Of Warrant Or Right expiration Date	Between 07/16/2020 and 08/13/2020 and 08/19/2020 and 09/09/2020
Series E1 Warrant [Member]
Class of Warrant or Right, Outstanding	186,557
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.50
Class Of Warrant Or Right expiration Date	Between 10/01/2020 and 11/12/2020 and 11/30/2020 and 12/09/2020
Series F1 Warrant [Member]
Class of Warrant or Right, Outstanding	292,499
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.00
Class Of Warrant Or Right expiration Date	8/11/2021
PIPE Warrants [Member]
Class of Warrant or Right, Outstanding	653,187
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 3.97
Class Of Warrant Or Right expiration Date	8/11/2021
Broker Warrants [Member]
Class of Warrant or Right, Outstanding	65,326
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.80
Class Of Warrant Or Right expiration Date	8/11/2021
Pipe Warrants1 [Member]
Class of Warrant or Right, Outstanding	1,503,567
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 3.97
Class Of Warrant Or Right expiration Date	6/22/2022
Brokers Warrants1 [Member]
Class of Warrant or Right, Outstanding	150,357
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 3.97
Class Of Warrant Or Right expiration Date	6/22/2022
Other Warrants [Member]
Class of Warrant or Right, Outstanding	194,796
Class Of Warrant Or Right expiration Date	Between 4/04/2018 and 9/01/2019
Other Warrants [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.20
Other Warrants [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 120
Series C2 warrant [Member]
Class of Warrant or Right, Outstanding	110,683
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6.00
Class Of Warrant Or Right expiration Date	1/13/2020
Series E2 warrant [Member]
Class of Warrant or Right, Outstanding	261,616
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 15.00
Class Of Warrant Or Right expiration Date	Between 10/01/2020 and 11/12/2020 and 11/30/2020 and 12/09/2020
Series F2 warrant [Member]
Class of Warrant or Right, Outstanding	290,834
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.20
Class Of Warrant Or Right expiration Date	8/11/2021
Series A2 warrant [Member]
Class of Warrant or Right, Outstanding	418,750
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.20
Class Of Warrant Or Right expiration Date	3/9/2020
Series C3 warrant [Member]
Class of Warrant or Right, Outstanding	2,083
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6.00
Class Of Warrant Or Right expiration Date	1/13/2020
Series D3 warrant [Member]
Class of Warrant or Right, Outstanding	416,667
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.00
Class Of Warrant Or Right expiration Date	Between 08/19/2020 and 09/09/2020
Series E3 warrant [Member]
Class of Warrant or Right, Outstanding	418,750
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 15.00
Class Of Warrant Or Right expiration Date	6/16/2020
Series F3 warrant [Member]
Class of Warrant or Right, Outstanding	416,667
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.20
Class Of Warrant Or Right expiration Date	8/11/2021

WARRANTS - Summary of number of price-reduced and price-retained warrants (Detail)	Dec. 31, 2017 $ / shares shares
Number of Warrant Shares Repriced [Member] \| Series C Warrant [Member]
Number of Warrant Shares \| shares	313,750
Number of Warrant Shares Repriced [Member] \| Series D Warrant [Member]
Number of Warrant Shares \| shares	312,500
Number of Warrant Shares Repriced [Member] \| Series F Warrant [Member]
Number of Warrant Shares \| shares	292,500
Pre-reduced Price [Member] \| Series C Warrant [Member]
Price	$ 6.00
Pre-reduced Price [Member] \| Series D Warrant [Member]
Price	9.00
Pre-reduced Price [Member] \| Series F Warrant [Member]
Price	7.20
Post-reduced Price [Member] \| Series C Warrant [Member]
Price	4.00
Post-reduced Price [Member] \| Series D Warrant [Member]
Price	4.00
Post-reduced Price [Member] \| Series F Warrant [Member]
Price	$ 4.00

WARRANTS- Additional Information (Detail)			1 Months Ended				12 Months Ended
WARRANTS- Additional Information (Detail)	May 12, 2017 USD ($)	Aug. 11, 2016 USD ($) $ / shares shares	Jun. 26, 2017 $ / shares $ / PerUnit shares	Jun. 23, 2017 USD ($) $ / shares shares	Aug. 31, 2016 USD ($) $ / shares shares	Aug. 25, 2016 USD ($) $ / shares $ / PerUnit shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Aug. 10, 2016 $ / shares shares	Dec. 31, 2015 shares
Class of Warrant or Right, Outstanding							6,520,000	5,059,000	3,096,665	4,343,000
Common Stock, Par or Stated Value Per Share \| $ / shares							$ 0.001	$ 0.001
Proceeds from Warrant Exercises \| $							$ 619,623	$ 5,483,349
Exercise Of Warrants Amount \| $							666,666	$ 5,483,349
Warrant [Member]
Exercise Of Warrants Amount \| $							$ 600,000
Private Placement [Member]
Class of Warrant or Right, Outstanding						65,317
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 3.97	$ 15.00	$ 6.00	$ 6.00	$ 3.97
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			653,187
Number Of Equity Units Issued						653,187
Equity Units Issued Price Per Unit \| $ / PerUnit						4.80
Aggregate Purchase Price Of Shares Agreed To Purchase Under Stock Purchase Agreement \| $						$ 3,100,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				168,000
Common Stock, Par or Stated Value Per Share \| $ / shares					$ 3.97	$ 0.001
Legal Fees \| $					$ 800,000	$ 800,000
Proceeds from Warrant Exercises \| $				$ 700,000
Number Of Equity Unit Issued					1,503,567
Class Of Warrant Or Right Warrant Price \| $ / shares			$ 0.125
Equity Unit Issued Price Per Unit \| $ / PerUnit			4.095			4.80
Number Of Units Sold			1,503,567	1,503,567
Aggregate Purchase Price Of Shares Agreed To Purchase Under Stock Purchases Agreement \| $					$ 6,200,000
Percentage of Aggregate Cash Fee for Placement Agent and Financial Advisory Services	10.00%
Non-accountable Expense Allowance \| $	$ 70,000
August 2016 Warrant Amendments [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares		$ 7.20
Stock Issued During Period, Shares, New Issues		750,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,000,000
Dividends \| $		$ 4,500,000
Series C Warrants [Member]
Class of Warrant or Right, Outstanding		583,333
Series C Warrants [Member] \| August 2016 Warrant Exercises [Member]
Class of Warrant or Right, Outstanding		583,333
Series C1 Warrant [Member]
Class of Warrant or Right, Outstanding		416,667					313,749
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares		$ 6.00					$ 4.00		$ 7.20
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									1,000,000
Proceeds from Warrant Exercises \| $		$ 6,000,000
Subsequent Warrant Issuance [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 3.97	$ 3.97
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			150,357
Class of Warrant or Right Term				5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				150,357
Class Of Warrant Or Right trancheTwo [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 4.50
Class Of Warrant Or Right tranche One [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 15.00
Class Of Warrant Or Right tranche One [Member] \| Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				187,000

STOCK OPTION PLANS - Stock Option Activity (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Number of Shares Outstanding, Ending Balance	533,000
Employee Stock Option [Member]
Number of Shares Outstanding, Begining Balance	434,095	298,679
Number of Shares, Granted	90,000	147,500
Number of Shares, Exercised		(10,417)
Number of Shares, Forfeited/expired	(34,840)	(1,667)
Number of Shares Outstanding, Ending Balance	489,255	434,095	298,679
Number of Shares, Options vested and exercisable	385,760
Weighted Average Exercise Price per Share Outstanding, Begining Balance	$ 7.41	$ 9.22
Weighted Average Exercise Price per Share, Granted	3.18	5.84
Weighted Average Exercise Price per Share, Exercised		1.74
Weighted Average Exercise Price per Share, Forfeited/expired	6.75	228.00
Weighted Average Exercise Price per Share Outstanding, Ending Balance	6.68	$ 7.41	$ 9.22
Weighted Average Exercise Price per Share Exercisable	$ 7.44
Total Intrinsic Value Outstanding	$ 107,000	$ 39,000	$ 177,000
Total Intrinsic Value, Exercisable	$ 41,000
Weighted Average Remaining Contractual Life, Outstanding	8 years 3 months 18 days	8 years 10 months 24 days	9 years 8 months 12 days
Weighted Average Remaining Contractual Life, Options granted	9 years 8 months 12 days	9 years 3 months 18 days
Weighted Average Remaining Contractual Life, Exercisable	8 years

STOCK OPTION PLANS - Weighted Average Assumptions (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Exercise price	$ 3.25	$ 5.84
Expected term (years)	10 years	9 years 8 months 12 days
Expected stock price volatility	217.00%	238.00%
Risk-free rate of interest	2.00%	2.00%
Expected dividend rate	0.00%	0.00%

STOCK OPTION PLANS - Cost Related to Unvested Awards Not Yet Recognized and the Weighted Average Periods (Detail)	12 Months Ended
	Dec. 31, 2017 USD ($)
Unrecognized stock-based compensation cost:	$ 262,000
Expected weighted average period compensation costs to be recognized (years):	8 months 12 days

STOCK OPTION PLANS - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 30, 2015	Dec. 31, 2017	Dec. 31, 2016	Aug. 29, 2017
Share-based Compensation		$ 2,738,244	$ 1,558,409
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				1,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		533,000
Research and Development Expense [Member]
Share-based Compensation		$ 100,000
Omnibus Stock Option Plan 2014 [Member]
Share-based Compensation		$ 2,600,000	$ 1,600,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	600,000

GRANT INCOME - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenue from Grants	$ 0.2	$ 0.2

CONTINGENCIES AND COMMITMENTS (Details)	Dec. 31, 2017 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2018	$ 116,000
2019	108,000
2020	111,000
2021	114,000
2022	68,000
Thereafter	0
Total	$ 517,000

CONTINGENCIES AND COMMITMENTS - Additional Information (Detail) - USD ($)		1 Months Ended	12 Months Ended
	Sep. 22, 2017	Aug. 25, 2016	Dec. 31, 2017	Dec. 31, 2016
Commitments And Contingencies [Line Items]
Operating Leases, Rent Expense, Net			$ 121,200	$ 82,500
Chief Operating Officer [Member]
Commitments And Contingencies [Line Items]
Salaries, Wages and Officers' Compensation	$ 362,500	$ 200,000
Annual Performance Bonus On Base Salary Percentage Eligible	50.00%	50.00%
Dr Glynn Wilson [Member]
Commitments And Contingencies [Line Items]
Salaries, Wages and Officers' Compensation	$ 12
Annual Performance Bonus On Base Salary Percentage Eligible	50.00%
Strategic Advisor [Member]
Commitments And Contingencies [Line Items]
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 300,000

INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Net operating loss carryforward	$ 13,653,000	$ 10,934,000
Stock-based compensation	2,231,000	2,066,000
License agreements	493,000	490,000
Research and development	117,000	117,000
Technology licensing fee	185,000	185,000
Valuation allowance	(16,679,000)	(13,792,000)
Deferred tax assets, net of valuation allowance	$ 0	$ 0

INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
U. S. federal statutory rate	$ (3,734,000)	$ (835,000)
State taxes, net of federal benefit	(414,000)	(286,000)
Federal tax rate change	1,401,000	0
Permanent differences
Permanent differences- Change in fair value of derivative liabilities	(2,000)	(2,019,000)
Permanent differences- Other permanent differences	(161,000)	46,000
Change in valuation allowance	2,890,000	2,966,000
Other	20,000	128,000
Income tax provision (benefit)	$ 0	$ 0

INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
U. S. federal statutory rate	(34.00%)	(34.00%)
State taxes, net of federal benefit	(3.60%)	(11.60%)
Federal tax rate change	12.30%	0.00%
Permanent differences
- Change in fair value of derivative liabilities	(0.00%)	(82.20%)
-Other permanent differences	(1.50%)	1.90%
Change in valuation allowance	26.30%	120.80%
Other	0.50%	5.20%
Income tax provision (benefit)	(0.00%)	0.00%

INCOME TAXES - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax [Line Items]
Stock Granted, Value, Share-based Compensation, Forfeited		$ 62,000
Reversal of deferred tax assets		$ 16,000
Tax credit carryforwards expiration period		2029
Deferred Tax Assets, Tax Credit Carryforwards, Research		$ 117,000	$ 117,000
Tax credit carryforwards expiration year end		2037
Deferred Tax Assets, Operating Loss Carryforwards, Foreign		$ 41,700,000
Deferred Tax Assets, Operating Loss Carryforwards, State and Local		21,900,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		$ 2,890,000	$ 2,966,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		34.00%	34.00%
Scenario, Plan [Member]
Income Tax [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Research Tax Credit Carryforward [Member]
Income Tax [Line Items]
Tax credit carryforwards expiration period		2029